155 related articles for article (PubMed ID: 12445424)
21. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
[TBL] [Abstract][Full Text] [Related]
22. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.
Chang ML; Chien RN; Yeh CT; Liaw YF
J Hepatol; 2005 Jul; 43(1):72-7. PubMed ID: 15896869
[TBL] [Abstract][Full Text] [Related]
23. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
24. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan.
Huang YH; Wu JC; Chang TT; Sheen IJ; Lee PC; Huo TI; Su CW; Wang YJ; Chang FY; Lee SD
J Viral Hepat; 2003 Jul; 10(4):277-84. PubMed ID: 12823594
[TBL] [Abstract][Full Text] [Related]
25. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
[TBL] [Abstract][Full Text] [Related]
26. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.
Ogata N; Fujii K; Takigawa S; Nomoto M; Ichida T; Asakura H
J Med Virol; 1999 Nov; 59(3):270-6. PubMed ID: 10502255
[TBL] [Abstract][Full Text] [Related]
27. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy.
Ciancio A; Smedile A; Rizzetto M; Lagget M; Gerin J; Korba B
Hepatology; 2004 Jan; 39(1):64-73. PubMed ID: 14752824
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.
Santantonio T; Mazzola M; Iacovazzi T; Miglietta A; Guastadisegni A; Pastore G
J Hepatol; 2000 Feb; 32(2):300-6. PubMed ID: 10707871
[TBL] [Abstract][Full Text] [Related]
29. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy.
Kim KH; Lee KH; Chang HY; Ahn SH; Tong S; Yoon YJ; Seong BL; Kim SI; Han KH
J Med Virol; 2003 Nov; 71(3):367-75. PubMed ID: 12966541
[TBL] [Abstract][Full Text] [Related]
30. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
[TBL] [Abstract][Full Text] [Related]
31. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion.
Chan HL; Hussain M; Lok AS
Hepatology; 1999 Mar; 29(3):976-84. PubMed ID: 10051506
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF
Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the hepatitis B virus precore and ORF-X sequences in patients with antibody to hepatitis B e antigen with and without normal ALT levels.
Cabrerizo M; Bartolomé J; Iñigo ER; López-Alcorocho JM; Cotonat T; Carreño V
J Med Virol; 1998 Dec; 56(4):294-9. PubMed ID: 9829632
[TBL] [Abstract][Full Text] [Related]
34. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
Suzuki F; Kumada H; Nakamura H
J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
[TBL] [Abstract][Full Text] [Related]
35. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
Revill PA; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin SR; Dore GJ; Matthews GV; Thio CL; Locarnini SA
AIDS; 2007 Aug; 21(13):1701-10. PubMed ID: 17690567
[TBL] [Abstract][Full Text] [Related]
36. [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects].
Yuan J; Zhou BP; Gong ZJ; Xu LM; Jiang XL; Mizokami M
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Mar; 20(1):30-2. PubMed ID: 16642214
[TBL] [Abstract][Full Text] [Related]
37. Mutations in the basal core promoter and precore/core gene of hepatitis B virus in patients with chronic active but not acute hepatitis B.
Mayerat C; Mantegani A; Spertini F; Frei PC
Eur J Clin Microbiol Infect Dis; 1999 Dec; 18(12):871-8. PubMed ID: 10691198
[TBL] [Abstract][Full Text] [Related]
38. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B.
Shindo M; Hamada K; Koya S; Sokawa Y; Okuno T
Am J Gastroenterol; 1999 Aug; 94(8):2237-45. PubMed ID: 10445556
[TBL] [Abstract][Full Text] [Related]
39. Detection of mutations in the enhancer 2/core promoter region of hepatitis B virus in patients with chronic hepatitis B virus infection: comparison with mutations in precore and core regions in relation to clinical status.
Honda A; Yokosuka O; Ehata T; Tagawa M; Imazeki F; Saisho H
J Med Virol; 1999 Apr; 57(4):337-44. PubMed ID: 10089043
[TBL] [Abstract][Full Text] [Related]
40. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.
Ryu SH; Chung YH; Choi MH; Kim JA; Shin JW; Jang MK; Park NH; Lee HC; Lee YS; Suh DJ
J Hepatol; 2003 Oct; 39(4):614-9. PubMed ID: 12971973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
